Pegasys®

BIOLOGICAL4 trials

Sponsors

Chugai Pharmaceutical, Novartis Pharmaceuticals, Gilead Sciences

Conditions

Chronic Hepatitis BChronic Hepatitis CChronic Hepatitis C InfectionHepatitis C, Chronic

Phase 1

Pharmacokinetic/Pharmacodynamic of Albinterferon Alfa-2b in Chronic Hepatitis B, eAg+, Infection Subjects

TerminatedNCT00964665

Novartis PharmaceuticalsChronic Hepatitis B

Start: 2009-07-31Updated: 2011-01-06

Phase 2

A Study of Response-Guided Duration of Combination Therapy With GS-9190, GS-9256, Pegasys® and Copegus® in Previously Untreated Subjects With Genotype 1 Chronic Hepatitis C

CompletedNCT01225380

Gilead SciencesChronic Hepatitis C Infection

Start: 2010-10-31End: 2013-09-30Updated: 2014-01-28

A Study of Response-Guided Duration of Combination Therapy With GS-9451, Pegasys® and Copegus® With and Without Tegobuvir (GS-9190) in Previously Untreated Subjects With Genotype 1 Chronic Hepatitis C

CompletedNCT01271790

Gilead SciencesHepatitis C, Chronic

Start: 2010-10-31End: 2013-09-30Updated: 2014-02-06

Phase 4

Trial of Pegasys® in Patients With Chronic Hepatitis C

CompletedNCT00245414

Chugai PharmaceuticalChronic Hepatitis C

Start: 2005-10-31End: 2010-07-31Updated: 2010-11-17

Related Papers

Randomized, controlled pharmacokinetic and pharmacodynamic evaluation of albinterferon in patients with chronic hepatitis <scp>B</scp> infection

Journal of Gastroenterology and Hepatology2014-07-048 citations